07:00 , Aug 10, 2009 |  BC Week In Review  |  Financial News

Senesco proposes private placement of common stock and warrants

Senesco Technologies Inc. (NYSE-A:SNT), New Brunswick, N.J.   Business: Cancer, Autoimmune, Agbio/Environmental   Date announced: 7/30/09   Type: Private placement of common stock and warrants   To be raised: Up to $704,999   Shares: 783,332...
08:00 , Nov 12, 2001 |  BC Week In Review  |  Clinical News

VEGF-2: Phase I/II studies update

Vascular Genetics Inc., Research Triangle Park, N.C.   Product: VEGF-2   Business: Cardiovascular   Therapeutic category: Angiogenesis, Gene therapy   Target: VEGF-2 receptors   Description: Vascular endothelial growth factor-2 (VEGF-2) gene therapy   Indication: Treat...
07:00 , May 2, 2000 |  BC Extra  |  Company News

FDA blasts Isner's VEGF trials

The FDA has accused Vascular Genetics Inc. founder Jeffrey Isner of violating regulations governing the conduct of clinical trials and human subject protections, putting subjects at risk in trials of Vascular Endothelial Growth Factor Plasmid...
08:00 , Mar 20, 2000 |  BC Week In Review  |  Clinical News

VEGF-2: Phase I/II

Researchers reported on a Phase I/II dose escalation study of VEGF-2 gene therapy in 30 patients with stable and refractory exertional angina who were not candidates for revascularization procedures. A total of 70 percent of...
08:00 , Mar 6, 2000 |  BC Week In Review  |  Clinical News

VEGF-2: Update

The company said it required more time than anticipated to develop an assay to measure systemic levels of VEGF-2, and that the FDA determined the trial should not go forward without the assay. Vascular Genetics...
08:00 , Feb 28, 2000 |  BC Week In Review  |  Company News

Human Genome Sciences, Vascular Genetics, Vical deal

The companies will develop products based on genes from HGSI's database using VICL's naked DNA delivery technology. VICL has the option to exclusively license up to three genes from HGSI, and HGSI has the option...
08:00 , Feb 25, 2000 |  BC Extra  |  Company News

Three way drug development deal

Vical (VICL), Human Genome Sciences (HGSI), and Vascular Genetics ( Research Triangle Park, N.C.), a joint venture between HGSI, St. Elizabeth's Medical Center and Cato Holding Co. ( Research Triangle Park, N.C.), entered an agreement...
08:00 , Feb 22, 1999 |  BioCentury  |  Tools & Techniques

Inflection points

As news watchers come to realize, seemingly independent events have a way of piling up on themselves and pushing other topics into the background. With the stars thus aligned, it becomes impossible to ignore the...
08:00 , Jan 4, 1999 |  BC Week In Review  |  Clinical News

Vascular endothelial growth factor-2 (VEGF-2) gene therapy: Began Phase I/II studies

Human Genome Sciences Inc. (HGSI), Rockville, Md.   Product: Vascular endothelial growth factor-2 (VEGF-2) gene therapy   Indication: Treat critical limb ischemia   Status: HGSI and its Vascular Genetics Inc. (Durham, N.C.) joint venture with...
08:00 , Mar 2, 1998 |  BioCentury  |  Tools & Techniques

Making angiogenesis work for the heart

Within a few years, if all goes well, patients with heart disease could have an alternative to the invasive procedures that are the norm for many today. Researchers are publishing the first clinical results using...